Artificial Intelligence in Cardiology Market Report 2025

The artificial intelligence in cardiology market size has grown exponentially in recent years. It will grow from $1.97 billion in 2024 to $2.72 billion in 2025 at a compound annual growth rate (CAGR) of 37.9%. The growth in the historic period can be attributed to increasing cardiovascular disease burden, big data availability, clinical decision support, growing importance of preventive cardiology, shortages in cardiovascular specialists.

The artificial intelligence in cardiology market size is expected to see exponential growth in the next few years. It will grow to $10.76 billion in 2029 at a compound annual growth rate (CAGR) of 41.1%. The growth in the forecast period can be attributed to integration with electronic health records, population aging, wearable devices, remote monitoring, global telecardiology adoption, integrated cardiovascular imaging. Major trends in the forecast period include technological innovations in cardiovascular diagnostics, advancements in ai algorithms, new drug development, advancements in medical imaging.

The anticipated rise in the prevalence of cardiovascular diseases is expected to drive the artificial intelligence in the cardiology market in the future. Cardiovascular diseases encompass various conditions affecting the heart and blood vessels. In the field of cardiology, AI plays a crucial role in disease detection by assisting in electrocardiogram (ECG) interpretation and identifying conditions such as long QT syndrome and atrial fibrillation. Additionally, AI can analyze extensive data from electronic health records, mobile health devices, and imaging data. For instance, a January 2022 article by the American Heart Association reported approximately 19.1 million global deaths attributed to cardiovascular disease in 2022. Furthermore, a May 2023 report from the Centers for Disease Control and Prevention revealed an increase in heart disease-related deaths in the US from 659,041 in 2019 to 695,000 in 2021. Thus, the global burden of cardiovascular diseases is a driving force for the artificial intelligence in cardiology market.

The growing adoption of wearable devices is expected to drive the growth of artificial intelligence in the cardiology market in the coming years. Wearable devices, commonly referred to as wearables, are electronic gadgets designed to be worn on the body, typically as accessories or clothing. They feature sensors, networking capabilities, and processing functions to collect data and monitor various health aspects. AI algorithms can analyze data from these wearables to identify subtle abnormalities that may indicate potential heart issues, such as arrhythmias, heart failure, and even stroke. For instance, according to Italian Watch Spotter, a community associated with luxury watch brands in Italy, 15.8 million watches were exported in 2022, up from 15.7 million in 2021. Therefore, the increasing adoption of wearable devices is driving the artificial intelligence market in cardiology.

The emergence of new AI-powered cardiology products is a notable trend in the artificial intelligence in cardiology market. Key companies in this market are dedicated to developing innovative AI-powered products for cardiology to strengthen their market position. For example, in February 2023, Eko Health, a US-based digital health company, introduced SENSORA, a digital stethoscope platform designed for detecting heart and lung diseases. SENSORA utilizes advanced machine learning and artificial intelligence to identify structural murmurs, a key indicator of valvular heart disease. This platform combines a stethoscope, one of the most widely used medical instruments globally, with the latest developments in applied machine learning for cardiovascular disease detection.

Major players in the artificial intelligence in cardiology market are actively pursuing strategic collaborations to revolutionize heart research. Strategic partnerships involve leveraging each other's strengths and resources for mutual benefits and success. For instance, in October 2023, the Icahn School of Medicine at Mount Sinai, a US-based medical school, announced a collaboration with Chiba Institute of Technology (CIT), a Japan-based private university. This collaboration aims to enhance knowledge, mitigation, and management of cardiovascular disease, as well as develop novel approaches to address this global health concern. Mount Sinai and CIT will collaborate on global clinical studies using artificial intelligence in interventional cardiology, heart failure, cardiac electrophysiology, cardiac imaging, and preventive cardiology. The research will also focus on reducing gender and race bias at the intersection of artificial intelligence and cardiovascular research to enhance patient care and outcomes.

In November 2022, Anumana, a US-based AI-driven health technology company, acquired NeuTrace for an undisclosed amount. This acquisition aims to position Anumana as a leader in AI medical software development for cardiac electrophysiology and expand the company's product portfolio. NeuTrace, a US-based medical device company, specializes in AI and Machine Learning to develop innovative diagnostics and solutions for heart disease.

Major companies operating in the artificial intelligence in cardiology market include Microsoft Corporation, International Business Machines Corporation, Siemens Healthineers, Koninklijke Philips, Tempus Labs Inc., Ultromics Ltd, Bay Labs, Cleerly Inc., RSIP Vision Ltd., Idoven, Cardiologs Technologies Inc., Viz.ai, Aidoc, Arterys Inc., Zebra Medical Vision, Vista.ai, AliveCor, DiA Imaging Analysis, Eko Health Inc., Cardiomatics, UltraSight, Anumana Inc., Cardiai Inc.

North America was the largest region in the artificial intelligence in cardiology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence in cardiology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence in cardiology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Artificial intelligence is applied in cardiology to predict cardiovascular outcomes, identify malignant arrhythmias, and non-invasively diagnose coronary artery disease. Its use encompasses the detection of heart disease, prompt stroke treatment, and the improvement of diagnostic radiology capabilities.

The essential components of artificial intelligence in cardiology include hardware, software solutions, and services. Hardware pertains to the components or delivery mechanisms responsible for storing and executing written instructions from specific software. In cardiology, artificial intelligence hardware is employed in treating various cardiovascular diseases, such as cardiac arrhythmia, stroke, ischemic heart disease, and coronary artery disease (CAD). Life science companies, healthcare payers, and healthcare providers utilize these technologies.

The artificial intelligence in cardiology research report is one of a series of new reports that provides artificial intelligence in cardiology market statistics, including the artificial intelligence in cardiology industry's global market size, regional shares, competitors with an artificial intelligence in cardiology market share, detailed artificial intelligence in cardiology market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence in cardiology industry. This artificial intelligence in cardiology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The artificial intelligence in cardiology market consists of revenues earned by entities by providing disease prediction, disease diagnosis, and automation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence market in cardiology also includes sales of smart robots, and imaging tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.